Telesis Bio (TBIO) EV/EBITDA Multiple
The Telesis Bio, Inc. (TBIO) market price chart demonstrates an EV/EBITDA ratio of . The business is protected by copyrights for nucleic acid synthesis systems and support from the scientific community under strict FDA oversight. Telesis Bio, Inc. (TBIO) is implementing desktop bioprinters, overcoming complexities in enzyme creation. Human capital is secured by a staff of synthetic biology experts who remain with the company due to the uniqueness of the developments.
telesisbio.com (TBIO) - metric breakdowns and financial figures
- market price and analyst price targets:
- market capitalization details:
- issuer book value statistics:
- company liabilities and liquidity data:
- business earnings and investment ratios data:
TBIO - Net Financial Result|Expected Profit Telesis Bio, Inc.|TBIO - Price to Earnings Multiple|Forward P/E Multiple Telesis Bio, Inc.|TBIO - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Telesis Bio, Inc|TBIO - Operating income before deduction of amortization|Net earnings per share for the last 12 months Telesis Bio|TBIO - Earnings per share for the last four quarters|Quarterly EPS earnings growth telesisbio.com|TBIO - Earnings per share growth in current year|Earnings growth forecast for next year Telesis Bio, Inc.
Comprehensive company analysis:TBIO (Codex DNA)
This indicator compares the total enterprise value, including debt, with its operating profit before taxes and amortization. A low ratio suggests the asset may be undervalued, yet it highlights the risk of high valuation sensitivity to any revenue fluctuations. Given the capital efficiency and the use of distributors by Telesis Bio, Inc. (TBIO), the company's current EV/EBITDA multiple reflects the effectiveness of its DNA synthesis systems monetization.
Competitor analysis
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|Total Company Value to Operating Income Before Depreciation Ratio Qiagen Corp (QGEN)|Ionis Pharmaceuticals - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio repligen.com RGEN|Avidity Biosciences, Inc. (RNA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRSP - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio WGS|RARE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BEAM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SRPT (sarepta.com)|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics Inc (TXG)|NTLA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Stoke Corp|BLFS (BioLife Solutions, Inc.) - Enterprise Value to EBITDA Ratio|wavelifesciences.com - Business Value to Operating Income Before Depreciation|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Sionna Therapeutics, Inc. (SION) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prime Medicine Corp (PRME)|Taysha Corp - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple QURE (uniQure N.V.)|MGTX - Enterprise Value to EBITDA Ratio|RGNX: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Solid Biosciences Inc SLDB|OCGN (Ocugen Corp) - Enterprise Value to EBITDA Ratio|PACB: Enterprise Value to Operating Income Before Depreciation Ratio|BNTC (Benitec Biopharma Inc.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DSGN|EV/EBITDA Multiple RCKT|Total Company Value to Operating Income Before Depreciation Ratio 4DMT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexeo Therapeutics, Inc. LXEO|Korro Bio Inc. (KRRO) - Company Value to EBITDA|Editas Medicine, Inc. - EV/EBITDA Multiple|SLN (silence-therapeutics.com) - Enterprise Value to Operating Income Before Depreciation|proqr.com (PRQR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation CDXS|SGMO (Sangamo) - EV/EBITDA Multiple|EV/EBITDA Multiple Nautilus Biotechnology Inc|Enterprise Value to EBITDA Ratio MGX (Metagenomi, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio DTIL|EV/EBITDA Multiple GBIO (Generation Bio)|Boundless Bio Inc. (BOLD) - Company Value to EBITDA|XCUR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IMNN: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PHIO: EV/EBITDA Multiple|Company Value to EBITDA Mustang Bio (MBIO)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TransCode Therapeutics Inc.|Bionano (BNGO) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple APDN|Total Company Value to Operating Income Before Depreciation Ratio bluebird bio, Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ImmunoPrecise Antibodies Ltd. IPA|Total Company Value to Operating Income Before Depreciation Ratio omegatherapeutics.com (OMGA)|OMIC: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RGLS (Regulus Therapeutics, Inc.)|SYRS: EV/EBITDA Multiple|TCON (TRACON Pharmaceuticals, Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UBX (Unity Biotechnology) - EV/EBITDA Multiple
